imatinib doc generici 100 mg, capsules
doc generici s.r.l. - imatinibmesilaat samenstelling overeenkomend met ; imatinib - capsule, hard - ammonia (e 527) ; gelatine (e 441) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; ijzeroxide zwart (e 172) ; magnesiumstearaat (e 470b) ; propyleenglycol (e 1520) ; schellak (e 904) ; titaandioxide (e 171) ; zwarte inkt, - imatinib
lutenyl 5 mg tabl.
theramex ireland ltd. - nomegestrolacetaat 5 mg - tablet - 5 mg - nomegestrolacetaat 5 mg - nomegestrol
nogest 5 mg tabl.
ceres pharma sa-nv - nomegestrolacetaat 5 mg - tablet - 5 mg - nomegestrolacetaat 5 mg - nomegestrol
sildenafil doc generici 100 mg, kauwtabletten
doc generici s.r.l. via filippo turati 40 20121 milano (italiË) - sildenafilcitraat 140,8 mg/stuk samenstelling overeenkomend met ; sildenafil 100 mg/stuk - kauwtablet - aspartaam (e 951) ; croscarmellose natrium (e 468) ; lactose 1-water ; magnesiumstearaat (e 470b) ; pepermuntsmaakstof ; polacriline kalium ; povidon k 30 (e 1201) ; siliciumdioxide (e 551), - sildenafil
sildenafil doc generici 25 mg, kauwtabletten
doc generici s.r.l. via filippo turati 40 20121 milano (italiË) - sildenafilcitraat 35,1 mg/stuk samenstelling overeenkomend met ; sildenafil 25 mg/stuk - kauwtablet - aspartaam (e 951) ; croscarmellose natrium (e 468) ; lactose 1-water ; magnesiumstearaat (e 470b) ; pepermuntsmaakstof ; polacriline kalium ; povidon k 30 (e 1201) ; siliciumdioxide (e 551), - sildenafil
sildenafil doc generici 50 mg, kauwtabletten
doc generici s.r.l. via filippo turati 40 20121 milano (italiË) - sildenafilcitraat 70,2 mg/stuk samenstelling overeenkomend met ; sildenafil 50 mg/stuk - kauwtablet - aspartaam (e 951) ; croscarmellose natrium (e 468) ; lactose 1-water ; magnesiumstearaat (e 470b) ; pepermuntsmaakstof ; polacriline kalium ; povidon k 30 (e 1201) ; siliciumdioxide (e 551), - sildenafil
deltyba
otsuka novel products gmbh - delamanid - tuberculose, multiresistente - antimycobacteriële - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 en 5. aandacht moet worden gegeven aan de officiële richtlijnen betreffende het juiste gebruik van antibacteriële agentia.
xarelto
bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antitrombotische middelen - xarelto, co-toegediend met acetylsalicylzuur (asa), alleen of met asa plus clopidogrel of ticlopidine, is geïndiceerd voor de preventie van atherothrombotic gebeurtenissen bij volwassen patiënten na een acuut coronair syndroom (acs) met verhoogde cardiale biomarkers. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. preventie van veneuze trombo-embolie (vte) bij volwassen patiënten die een electieve heup- of knievervangende operatie ondergaan. behandeling van diepe veneuze trombose (dvt) en longembolie (pe) en preventie van recidiverende dvt en pe bij volwassenen. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
stivarga
bayer pharma ag - regorafenib - colorectale neoplasma's - antineoplastic agents, protein kinase inhibitors - stivarga is geïndiceerd als monotherapie voor de behandeling van volwassen patiënten met:gemetastaseerde colorectale kanker (crc) die al eerder zijn behandeld met of worden niet beschouwd als kandidaten voor, therapieën - deze omvatten fluoropyrimidine-gebaseerde chemotherapie, een anti-vegf therapie en een anti-egfr-therapie;inoperabele of gemetastaseerde gastro-intestinale stromale tumoren (gist) die gevorderd op of intolerant zijn voor een voorafgaande behandeling met imatinib en sunitinib;hepatocellulair carcinoom (hcc) die eerder werden behandeld met sorafenib.
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotische middelen - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.